0000000000740297

AUTHOR

N Kianipour

showing 3 related works from this author

The prevalence of onchocerciasis in Africa and Yemen, 2000-2018: a geospatial analysis.

2022

Abstract Background Onchocerciasis is a disease caused by infection with Onchocerca volvulus, which is transmitted to humans via the bite of several species of black fly, and is responsible for permanent blindness or vision loss, as well as severe skin disease. Predominantly endemic in parts of Africa and Yemen, preventive chemotherapy with mass drug administration of ivermectin is the primary intervention recommended for the elimination of its transmission. Methods A dataset of 18,116 geo-referenced prevalence survey datapoints was used to model annual 2000–2018 infection prevalence in Africa and Yemen. Using Bayesian model-based geostatistics, we generated spatially continuous estimates o…

Onchocerciasis; Geospatial model; Neglected tropical diseases;IvermectinYemenSettore MED/06 - Oncologia MedicaSettore MED/42 - Igiene Generale e ApplicataNigeriaBayes TheoremGeneral MedicineOnchocerciasisGhanaSettore MED/01 - Statistica MedicaGeneral & Internal MedicinePrevalenceHumansGeospatial model11 Medical and Health SciencesNeglected tropical diseasesBMC medicine
researchProduct

Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018

2021

Anemia is a globally widespread condition in women and is associated with reduced economic productivity and increased mortality worldwide. Here we map annual 2000–2018 geospatial estimates of anemia prevalence in women of reproductive age (15–49 years) across 82 low- and middle-income countries (LMICs), stratify anemia by severity and aggregate results to policy-relevant administrative and national levels. Additionally, we provide subnational disparity analyses to provide a comprehensive overview of anemia prevalence inequalities within these countries and predict progress toward the World Health Organization’s Global Nutrition Target (WHO GNT) to reduce anemia by half by 2030. Our results …

Psychological interventionDiseasesResearch & Experimental MedicineGlobal HealthPrevalence11 Medical and Health Sciencesmedia_commonCHILD GROWTH FAILUREPublic Health Global Health Social Medicine and EpidemiologyAnemiaGeneral MedicineMiddle AgedanemiaPeer reviewIRON-DEFICIENCYNutritional StatuPREGNANCYMedicine Research & ExperimentalScale (social sciences)reproductive age/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingA990 Medicine and Dentistry not elsewhere classifiedFemalewomenLife Sciences & Biomedicinevulnerable populationsHumanAdultmedicine.medical_specialtyBiochemistry & Molecular BiologyInequalityAdolescentAnemiamedia_common.quotation_subjectMODELSImmunologyNutritional StatusReproductive ageLocal Burden of Disease Anaemia CollaboratorsGeneral Biochemistry Genetics and Molecular BiologyDeveloping CountrieYoung AdultSDG 3 - Good Health and Well-beingEnvironmental healthmedicineLife ScienceHumansDeveloping CountriesPovertyGlobal NutritionPregnancyWereldvoedingScience & Technologybusiness.industryPublic healthCell BiologyGLOBAL BURDENmedicine.diseaseFolkhälsovetenskap global hälsa socialmedicin och epidemiologiRisk factors1182 Biochemistry cell and molecular biology3111 Biomedicinebusiness
researchProduct

Mapping routine measles vaccination in low- and middle-income countries

2021

The safe, highly effective measles vaccine has been recommended globally since 1974, yet in 2017 there were more than 17 million cases of measles and 83,400 deaths in children under 5 years old, and more than 99% of both occurred in low- and middle-income countries (LMICs)1–4. Globally comparable, annual, local estimates of routine first-dose measles-containing vaccine (MCV1) coverage are critical for understanding geographically precise immunity patterns, progress towards the targets of the Global Vaccine Action Plan (GVAP), and high-risk areas amid disruptions to vaccination programmes caused by coronavirus disease 2019 (COVID-19)5–8. Here we generated annual estimates of routine childhoo…

and promotion of well-beingVacunación MasivaInternationalityDisease preventionchildren under 5 years oldGeographic MappingRural Healthmedicine.disease_causeCross-reactivity0302 clinical medicineRA0421Vaccination Refusal030212 general & internal medicineChildimmunity patternsPediatric0303 health sciencesPublic healthMultidisciplinarybiologyVaccinationUncertaintyIMMUNIZATION3142 Public health care science environmental and occupational healthCOVERAGE3. Good healthTIME3.4 VaccinesChild PreschoolInfectious diseasesA990 Medicine and Dentistry not elsewhere classifiedAntibodyEngineering sciences. TechnologyAFRICAGeneral Science & TechnologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Disease prevention ; COVID-19 ; Public health ; Infectious diseases610 Medicine & healthGlobal Vaccine Action Plan (GVAP)Local Burden of Disease Vaccine Coverage CollaboratorsArticleVaccine Related03 medical and health sciencesmeasles vaccineMeasels ; Vaccination ; Low- and middle-income countries ; Local burden of disease ; Public healthClinical ResearchmedicineHumansHealthcare DisparitiesPreschoolPROGRESS030304 developmental biologybusiness.industryMORTALITYDeveloped CountriesPreventionCommentVacunaciónUrban HealthCOVID-19Prevention of disease and conditionsVirologyCoronavirusGood Health and Well BeingCobertura de Vacunaciónbiology.proteinImmunizationbusinessMeasles
researchProduct